Podcasts about Pancreatic cancer

Dr Bill Nelson speaks with Dr Elizabeth Jaffee about her research in cancer vaccines, immunotherapy, and the importance of federal funding in continuing to achieve breakthroughs in cancer treatment.

BUFFALO, NY - June 17, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 10, 2025, titled “Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence.” The study, led by first author Kavin Sugumar and corresponding author Jordan M. Winter, from University Hospitals Seidman Cancer Center, reports on a rare group of pancreatic cancer (PC) patients who responded remarkably well to immunotherapy, a treatment typically considered ineffective for this cancer type. The analysis, which includes data from 14 patients across multiple U.S. institutions, identifies outcomes that could help refine treatment strategies for one of the most aggressive and deadly forms of cancer. “Between 2020–21, 471 oncologists from 91 major cancer centers in the United States were contacted.” Pancreatic cancer has among the lowest survival rates and few effective therapies. While immunotherapy has transformed the treatment landscape for several other cancers, it generally offers little benefit for pancreatic cancer. However, this study highlights a small but important group of patients who experienced significant and sustained responses to immune-based treatment without chemotherapy. Most had advanced or metastatic disease and had already progressed after standard treatments. Among the 14 patients, 82% had partial tumor shrinkage, and nearly one-third had a notable decrease in tumor markers. The median progression-free survival was 12 months, and most patients were still alive at follow-up, with survival rates of 80% at one year and 70% at two years. These outcomes contrast sharply with standard therapies, which often provide only a few months of benefit for similar patients. Interestingly, while some patients had high microsatellite instability (MSI-high)—a known marker for immunotherapy success—more than half did not, suggesting other biological mechanisms may be involved. This result highlights the need for new biomarkers to be discovered to predict treatment response in future studies. This case series is the largest focused exclusively on exceptional immunotherapy responders in pancreatic cancer. By excluding patients who received chemotherapy, the study isolates the effects of immune-based drugs, including PD-1 inhibitors such as pembrolizumab and nivolumab, CTLA-4 inhibitors like ipilimumab, and agents targeting macrophages. While the sample size is small, the findings challenge the assumption that immunotherapy is ineffective for nearly all pancreatic cancer patients. The study suggests that, under certain biological conditions, this treatment can be remarkably successful. Further research is needed to understand the underlying mechanisms. This work supports the need to reconsider how clinical trials are designed for pancreatic cancer and who is eligible for immunotherapy. Broader criteria and more personalized molecular profiling could help uncover hidden opportunities for treatment in this highly lethal cancer. DOI - https://doi.org/10.18632/oncotarget.28739 Correspondence to - Jordan M. Winter - jordan.winter@UHHospitals.org Video short - https://www.youtube.com/watch?v=VeWTcuVmqgM Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28739 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Dr Bill Nelson talks with Dr Denis Wirtz about his research using CODA, an artificial intelligence platform, to identify and analyze pre-cancerous lesions previously undetected in the pancreas and along the fallopian tubes.

AGNTCY - Unlock agents at scale with an open Internet of Agents. Visit https://agntcy.org/ and add your support. What if your blood could reveal the future of your health - years before symptoms ever appear? In this episode of Eye on AI, Craig Smith sits down with Ash Anwar, co-founder of Molecular You, to explore how AI and advanced biomarker analysis are transforming how we detect and prevent disease.  From a real-life case where stage 1 pancreatic cancer was caught early, to the science behind tracking 250+ dynamic biomarkers, Ash breaks down how Molecular You is shifting healthcare from reactive treatment to proactive longevity.  They dive into the limitations of genetic testing, the power of machine learning models trained on clinical data, and how personalized action plans are helping individuals take control of their health in real time.  If you're curious about the intersection of AI, diagnostics, and the future of preventive medicine—this is a conversation you won't want to miss. Stay Updated: Craig Smith on X: https://x.com/craigss Eye on A.I. on X: https://x.com/EyeOn_AI (00:00) How AI Can Predict Disease Before It Happens   (02:02) Meet Ash Anwar: From Scientist to Health Tech Leader   (06:31) What Is Molecular You and How It Works   (09:43) Why Biomarker Tracking Over Time Is a Game-Changer   (15:46) How Molecular You Detected Stage 1 Pancreatic Cancer   (23:15) Biomarkers vs Genetics: What Really Matters   (28:11) The AI Models Behind Early Disease Detection   (32:37) How the Product Works for Clinics and Consumers   (35:05) Who They Compete With and What Makes Them Different   (37:34) Research vs Product: The Cancer Risk Challenge   (43:43) How Often Should You Get Tested?

Dr. John Sweetenham shares highlights from Day 2 of the 2025 ASCO Annual Meeting, including new data on the treatment of ER+/HER2-negative breast cancer and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high risk of recurrence.  Transcript Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, your host of the ASCO Daily News Podcast, welcoming you to our special coverage of the 2025 ASCO Annual Meeting. Today, I'll be bringing you my takeaways on selected abstracts from Day 2 of the Meeting. My disclosures are available in the transcript of this episode.  Today's selection features important, new data on the treatment of ER-positive, HER2-negative breast cancer, the use of tumor treating fields in combination with chemotherapy for locally advanced pancreatic cancer, and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high-risk of recurrence.  Our first selected abstract is LBA1000. This important phase 3 study was presented by Dr. Erika Hamilton from the Sarah Cannon Research Institute in Nashville and evaluated the use of a novel agent, vepdegestrant, in patients with ER-positive/HER2-negative breast cancer, which had progressed after first-line endocrine therapy. Vepdegestrant is a selective oral PROTAC estrogen receptor degrader, which targets wild-type and mutant estrogen receptor through a novel mechanism of action which directly harnesses the ubiquitin-proteasome system to degrade ER. It has potential advantages over fulvestrant, a selective ER degrader which has to be administered intramuscularly and has limited benefit in patients who progress after endocrine therapy plus a CDK4/6 inhibitor.  Building on the encouraging results from the initial phase 1/2 study of vepdegestrant, Dr. Hamilton reported results from the VERITAC-2 global phase 3 trial, comparing this agent with fulvestrant. The patients in the study had already received treatment with hormone therapy and a CDK inhibitor and were randomly assigned to receive treatment with either vepdegestrant (313 patients) or fulvestrant (311 patients). The vepdegestrant was taken orally each day, while the fulvestrant was given intramuscularly on days 1 and 15 of the first cycle of treatment and day 1 of each subsequent treatment cycle. Patients were stratified by the presence of wild-type ER or ESR1 mutation. A total of 43.3% of patients had ESR1 mutations; 136 of those were in the vepdegestrant group and 134 in the fulvestrant group.   For patients with ESR1 mutations, vepdegestrant significantly increased progression-free survival compared with fulvestrant. For patients who received vepdegestrant, the median PFS was 5 months versus 2.1 months for those who received fulvestrant. The clinical benefit rate was 42.1% in the vepdegestrant group vs. 20.2% in the fulvestrant group. The overall response rate was 18.6% in the vepdegestrant group compared with only 4% in the fulvestrant group.  The PFS and response benefits of vepdegestrant were largely restricted to the population with ESR1 mutations. Overall survival data are currently immature. The safety profile was favorable, with fewer than 5% of patients having dose reductions or discontinuation due to toxicity. The most frequent toxicities were fatigue, nausea, and elevated transaminases.  The authors concluded that oral vepdegestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival compared with fulvestrant in this group of patients with ESR1-mutated ER+/HER2- advanced breast cancer who have progressed after endocrine therapy and a CDK inhibitor. Patients with recurrent disease in this context are now routinely tested for ESR1 mutations, and this agent is for sure a potential treatment option for them.  The next study on today's episode, LBA4005, reports on the use of tumor treatment fields for patients with locally advanced pancreatic cancer. Tumor treatment fields are electric fields which disrupt cell division and may also induce an enhanced immune response, using a non-invasive portable device attached to the skin, and are already approved for the treatment of some cancers, including GBM and non-small cell lung cancer. A previous phase 2 trial, PANOVA-2, confirmed the feasibility and safety of using this approach in combination with gemcitabine plus or minus nabpaclitaxel in pancreatic cancer. In today's presentation, Dr. Vincent Picozzi from the Virginia Mason Medical Center in Seattle presented the results of the PANOVA-3 trial, a phase 3 study comparing gemcitabine and nabpaclitaxel with the same chemotherapy plus tumor treatment fields in patients with locally advanced pancreatic adenocarcinoma.  Five hundred and seventy-one eligible patients were enrolled in the study with a total of 405 (198 in the treatment field group and 207 in the standard arm) comprising the modified intent- to-treat population. The duration of chemotherapy treatment was comparable in both study arms, and patients receiving treatment fields had a median exposure of almost 27 weeks.  Statistically significant improvements were observed for several study endpoints, including overall survival (a median of 16.2 versus 14.2 months), distant PFS (at 13.9 versus 11.5 months) and pain-free survival (at 15.2 versus 9.1 months), all in favor of the treatment fields arm. Although quality of life data were not reported in detail, the authors noted a significant improvement in global health status in the treatment fields arm. Safety data showed a higher level of skin adverse events in the treatment fields arm but were otherwise as expected for the GnP combination.  These are quite remarkable results which add to the growing evidence base for tumor treatment fields and are particularly compelling in this patient group given the substantial improvement in pain-free survival. It will be especially interesting to see the mature analysis of the quality-of-life endpoints in a subsequent report.  The final selection today is Abstract 6001, which describes the C-POST trial, a phase 3 trial of adjuvant cemiplimab versus placebo in patients with high-risk cutaneous squamous cell carcinoma of the skin. This study was presented by Dr. Danny Rischin from the Peter MacCallum Cancer Centre in Melbourne, Australia.   Although surgical resection with or without adjuvant radiation is curative in 90% of patients with cutaneous squamous cell carcinoma, high-risk features, including nodal disease, skin and subcutaneous metastases, perineural invasion and bone involvement, predict for an inferior prognosis.  Cemiplimab, a PD-1 targeting antibody is standard therapy for patients with locally advanced or metastatic disease who are not candidates for curative surgical resection or radiation therapy, with an overall response rate of almost 50%.  The C-POST study evaluated the use of cemiplimab as adjuvant therapy following surgery and radiation in high-risk patients, compared with placebo. Treatment was administered at 3-week intervals for 12 weeks, and then 6-week intervals for a further 36 weeks, with a primary endpoint of disease-free survival. Four hundred and fifteen patients were randomized in the study, 209 to cemiplimab and 206 to placebo. With median follow-up at 24 months, Dr. Rischin reported a highly significant improvement in disease-free survival for the cemiplimab arm, 49.4 months for placebo versus not reached for cemiplimab, with improvements also observed in the rates of locoregional recurrence and distant recurrence at 80% and 60% reductions, respectively. No new safety signals were observed.  This study is potentially practice-changing and provides strong evidence that cemiplimab should be considered the new standard of care in this clinical context.  Thanks for listening today and join me again tomorrow to hear more top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.  Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speaker:   Dr. John Sweetenham   Follow ASCO on social media:    @ASCO on Twitter   @ASCO on Bluesky   ASCO on Facebook   ASCO on LinkedIn    Disclosures:   Dr. John Sweetenham:   No relationships to disclose  

Featuring perspectives from Dr Farshid Dayyani, Ms Caroline Kuhlman, Dr Philip A Philip and Ms Amanda K Wagner, including the following topics: Introduction: Initial Management of Pancreatic Adenocarcinoma (PAD) (0:00) Clinical Presentation and Prognosis of PAD; Recent Advances in Up-Front Treatment for Metastatic PAD (19:01) Selection and Sequencing of Therapy for Relapsed/Refractory Metastatic PAD (54:38) Importance of Palliative Care for Advanced PAD (1:06:09) Role of PARP Inhibitor Maintenance Therapy for Newly Diagnosed Metastatic PAD (1:14:59) Promising Investigational Strategies for PAD (1:26:56) NCPD information and select publications

Drs Farshid Dayyani and Philip A Philip and oncology nursing professionals Caroline Kuhlman and Amanda K Wagner discuss datasets guiding treatment decision-making for patients with metastatic pancreatic cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.

Drs Farshid Dayyani and Philip A Philip and oncology nursing professionals Caroline Kuhlman and Amanda K Wagner discuss datasets guiding treatment decision-making for patients with metastatic pancreatic cancer and strategies to mitigate and manage treatment-emergent adverse events. CME information and select publications here.

Drs Farshid Dayyani and Philip A Philip and oncology nursing professionals Caroline Kuhlman and Amanda K Wagner discuss datasets guiding treatment decision-making for patients with metastatic pancreatic cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.

Everything on the Internet is true, right? What can Tik Tok (and social media) teach us about getting out of debt?  How much of the advice is legitimate and how much is, shall we say, a bit "out there"? On this week's episode of the Crushing Debt Podccast, Shawn & George watch (or listen to) Tik Tok videos from influencers who are trying to help people get out of debt. We'll then comment on the good, the bad, and the ugly of the advice given. As with any social media platform, you have to do your own due diligence and utilize strategies that will work for you. You can listen to similar former episodes of the show like Episode 413 - Tik Tok Money Hacks Episode 388 - Money Lessons from Tik Tok (our Girl Math Episode) The Tik Toks on this weeks episode cover topics such as: What is a normal amount of savings? Bankruptcy Frugal Hacks How to turn $60 into $1,000 Girl Math Why NOT to save money Let us know if you enjoy this episode and, if so, please share it with your friends! Please also visit our sponsor Sam Cohen of Attorneys First Insurance for Attorneys and Title Companies looking to get a quote on Errors & Ommissions (malpractice) Insurance coverage. www.AttorneysFirst.com.   Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com.  And please consider a donation to Pancreatic Cancer research and education by joining Shawn's team at MY Legacy Striders (the link will be live until June 2025): http://support.pancan.org/goto/MYLegacy8  

In this episode we are exploring two publications related to cancer care. In our first segment we talk to 2 authors about their research on genetic counselors and identification of patients for high-risk pancreatic cancer screening. In our second segment, Khalida interviews a genetic counselor about their study to evaluate surgical patient perspectives of genetic testing provided by a non-genetics professional.  Segment 1: “Practices and perspectives of genetic counselors about high-risk pancreatic cancer screening: A cross-sectional survey study” Amy Wiegand is a board-certified genetic counselor who specializes in cancer genetics. She graduated with her Master's in Genetic Counseling in 2017 from from the Icahn School of Medicine at Mount Sinai and has worked as a cancer genetic counselor at the Smilow Cancer Genetics and Prevention Program at Yale-New Haven Health since 2017 where she has seen over 2500 patients for a variety of hereditary cancer indications. Her research interests include hereditary pancreatic cancer and alternative delivery care models for genetic testing. Aparna is a senior genetic counseling assistant (GCA) at Smilow Cancer Genetics and Prevention Program at Yale New Haven Health where she has worked since 2019, and she has over 6 years of experience as a GCA. She holds a Master's degree in Biomedical Genetics and a Bachelor's degree in Biotechnology. She also has a varied background in administration, finance and customer service. She is a high-performing individual and was recently recognized by her colleagues as ‘Employee of the Quarter' and honored by the organization as ‘Smilow Star' for consistently going above and beyond for the patients and the co-workers and for exemplifying the health system's values. She contributes to the program in a variety of other ways outside of her role and works collaboratively with the team to create a patient centered environment. She has a strong interest in Cancer Genetics and is passionate about research. She is currently working on another research project, the abstract of which was selected for presentation in a Poster Session at 2025 ASCO (American Society of Clinical Oncology) annual meeting. She enjoys being part of a collaborative and dynamic team at Smilow Cancer Genetics and Prevention program and is excited about the upcoming research initiatives in the program. In this segment we discuss: - The significance of pancreatic cancer surveillance for high-risk individuals and why early detection plays a critical role in improving outcomes. - How genetic counselors are uniquely positioned to identify and refer individuals at high risk for pancreatic cancer, emphasizing their role in screening efforts. - An overview of the 2019 CAPS (Cancer of the Pancreas Screening) consensus guidelines and how they are applied to identify high-risk individuals for surveillance - The finding that nearly 70% of genetic counselors accurately identified individuals eligible for screening and discussed the factors that may have contributed to this high rate. - The association between provider comfort level and accuracy in identifying high-risk individuals, and discussed strategies to improve provider confidence and access to screening programs.   Segment 2: “Patient experiences of cancer genetic testing by non-genetics providers in the surgical setting” Katie Fiallos is a board-certified genetic counselor who earned her Master of Science in Genetic Counseling from the Johns Hopkins University/National Human Genome Research Institute Genetic Counseling Training program in 2017 and worked for seven years as a cancer genetic counselor at Johns Hopkins. She joined the Department of Medical and Molecular Genetics at Indiana University in August 2024. She is fluent in Spanish and provides genetic counseling in English and Spanish to participants with Parkinson's disease enrolled in the PD GENEration study. She has authored several academic papers related to genetic counseling, and her current research interests include provision of genetic counseling to Latine individuals, alternate service delivery models, and patient experiences with genetic testing and their informational desires. She lives in Michigan with her family and enjoys staying active, particularly practicing aerial silks. The research for the paper we're discussing was done while she was at Johns Hopkins and was funded by the Jennifer L. Brager Memorial Research award through the Johns Hopkins Kimmel Cancer Center.   In this segment we discuss: - Why hereditary cancer genetic testing is becoming increasingly important for patients with breast cancer, especially in relation to surgical decision-making. - The findings that patients preferred genetic testing at an existing appointment shortly after diagnosis, and explored how this timing affects their overall experience. - How many patients had already considered or wanted genetic testing before it was offered, shedding light on patient awareness and readiness. - Why patients were primarily motivated by concern for relatives and a desire for complete information, rather than surgical decision-making. - Gaps in patient-provider communication identified in the study and suggested ways for providers to address these issues in clinical practice.   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.  DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Sydney Arlen.

Why are garage sales the perfect sales and negotiation training ground? What is the golden rule of negotiating? What are some negotiation tactics that work, and some that don't? Each year, in October and May, Shawn's neighborhood hosts a community-wide garage sale. Shawn has tested and practiced different sales techniques at these bi-annual events in a low-risk, low-pressure environment! Please go back and listen to these previous garage sale episodes, which have covered lessons such as: 68 - negotiations 86 - preparation 118 - patience 168 - preparation 241 - approach 270 - target market 373 - delegate 393 - sales presentation In this week's episode, Shawn & George talk about the benefits of practicing negotiation skills at a garage sale, some negotiation tactics that have worked for them and some that have not worked for them, and getting the younger generations involved early in selling and negotiation (lessons taught to Shawn's kids). Let us know if you enjoy this episode and, if so, please share it with your friends! Please also visit our sponsor Sam Cohen of Attorneys First Insurance for Attorneys and Title Companies looking to get a quote on Errors & Ommissions (malpractice) Insurance coverage. www.AttorneysFirst.com.   Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com. And please consider a donation to Pancreatic Cancer research and education by joining Shawn's team at MY Legacy Striders: http://support.pancan.org/goto/MYLegacy8  This link will be live until June 1, 2025, and then we start on the 2026 team and fundraiser.

Featuring perspectives from Dr Paul E Oberstein and Dr Philip A Philip, including the following topics: Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Adenocarcinoma (PAD) — Dr Oberstein (0:00) Biomarker-Based Strategies for Metastatic PAD; Novel Investigational Approaches — Dr Philip(30:57) CME information and select publications

Clinical investigators discuss available data guiding the management of pancreatic cancer.  CME information and select publications here.

Clinical investigators discuss available data guiding the management of pancreatic cancer.  CME information and select publications here.

Clinical investigators discuss available data guiding the management of pancreatic cancer.  CME information and select publications here.

“I've given myself the title of ‘cat with nine lives.'” In this inspiring episode of the Project Purple Podcast, host Dino Verrelli talks with Toni Bravo, a pancreatic cancer survivor and student at the University of Notre Dame, to share her incredible cancer journey. Toni opens up about the shocking moment she was diagnosed during her junior year of college. The diagnosis came after an accident where she was hit by a car in a crash. Despite an initial CT scan missing the tumor, Toni's instincts told her something was wrong. Two months later, a follow-up CT scan revealed the truth. Toni reflects on how her life changed when she received the diagnosis alone, away from home. Her personal mantras, “Everything happens for a reason” and “Focus on the things you can control,” helped her navigate the challenges she faced. “I've always looked at everything as a redirection of my life. I've always had a pretty optimistic outlook,” she says. Drawing on childhood lessons, like adaptability, Toni shares how her experience taught her to cherish time. Throughout the conversation, Toni talks about the impact cancer had on her life as a young adult, processing the surgery to remove the tumor, how it changed her college career, grappling with mortality at just 20 years old, and finding peace. Her story is a powerful testament to hope, resilience, and strength. Subscribe to the Project Purple Podcast for more powerful stories from the pancreatic cancer community. If you'd like to donate to Project Purple's mission of a world without pancreatic cancer, please visit https://www.projectpurple.org/. To learn more about Project Purple, visit https://www.projectpurple.org/ or follow us on social media at these links: https://www.facebook.com/Run4ProjectPurple https://www.instagram.com/projectpurple/ https://twitter.com/Run4Purple https://www.youtube.com/channel/UCgA8nVhUY6_MLj5z3rnDQZQ

Send us a textAndy Campbell is a resilient survivor and inspirational author who has overcome numerous life-altering challenges - a victim of childhood sexual abuse and bullying, the loss of his mother at an early age and the eventual estrangement from his father, his battle with stage 4 pancreatic cancer, and the loss of his youngest son to suicide. Despite enduring multiple surgeries, grueling chemotherapy treatments, and the tragic loss of his youngest child, Andy has demonstrated remarkable strength and perseverance. Through his experiences, he has developed a unique perspective on resilience and the power of his 15 core beliefs.Andy lives with his wife and remains actively engaged in the lives of his three remaining adult children as he continues to support his family while managing his own health challenges. His book “Overcoming Life's Toughest Setbacks” shares the principles that have helped him navigate life's darkest moments, offering hope and guidance to others facing adversity.Join us for this moving, powerful, and inspirational episode! thanks Andy!https://www.askandycampbell.com/Support the show

Why are garage sales the perfect sales and negotiation training ground? What is the golden rule of negotiating? What are some negotiation tactics that work, and some that don't? Each year, in October and May, Shawn's neighborhood hosts a community-wide garage sale. Shawn has tested and practiced different sales techniques at these bi-annual events in a low-risk, low-pressure environment! Please go back and listen to these previous garage sale episodes, which have covered lessons such as: 68 - negotiations 86 - preparation 118 - patience 168 - preparation 241 - approach 270 - target market 373 - delegate 393 - sales presentation In this week's episode, Shawn & George talk about the benefits of practicing negotiation skills at a garage sale, some negotiation tactics that have worked for them and some that have not worked for them, and getting the younger generations involved early in selling and negotiation (lessons taught to Shawn's kids). Let us know if you enjoy this episode and, if so, please share it with your friends! Please also visit our sponsor Sam Cohen of Attorneys First Insurance for Attorneys and Title Companies looking to get a quote on Errors & Ommissions (malpractice) Insurance coverage. www.AttorneysFirst.com.   Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com. And please consider a donation to Pancreatic Cancer research and education by joining Shawn's team at MY Legacy Striders: http://support.pancan.org/goto/MYLegacy8  This link will be live until June 1, 2025, and then we start on the 2026 team and fundraiser.

Mark and Brittany speak with WSET Meterologist Will Stafford about his bike ride for Pancreatic Cancer.

Have you been paying your Student Loans? Have you been waiting on forgiveness of your Student Loans? Recently, the Department of Education has begun collection efforts for Student Loan borrowers behind on their payments, who have not repaid their debts or entered into some type of workout plan regarding their Student Loan debts. The government estimates that there are 6.4 million Student Loan borrowers between the ages of 50 - 60, that owe a combined $282 Billion - or $46,000 per borrower. For some history or background, Student Loan payments paused during the COVID pandemic. But in October 2023, Student Loan payments resumed (subject to any workout plan negotiated with the Department of Education).  Now, the government is seeking collection against any defaulted Student Loans, and they have as tools, the authority, under certain circumstances, to: (1) garnish wages, (2) intercept and retain tax refunds, and (3) intercept and retain social security payments. Unfortunately, Student Loans are still largely non-dischargeable under Bankruptcy Law, although there have been some in-roads. So how can you manage?  There are still options available, including: Income-Driven Repayment. Public Service Loan Forgiveness (PSLF) Modification You can also plan ahead for the costs of Education, by researching the different borrowing programs, Grants, 529 (and similar) plans. Let us know if you enjoy this episode and, if so, please share it with your friends! Please also visit our sponsor, Sam Cohen of Attorneys First Insurance for Attorneys and Title Companies looking to get a quote on Errors & Ommissions (malpractice) Insurance coverage. www.AttorneysFirst.com.   Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com.  And although the 2025 Purple Stride Walk is over, please consider a donation to Pancreatic Cancer research and education by joining Shawn's 2025 Team at MY Legacy Striders: http://support.pancan.org/goto/MYLegacy8  The link will be available until June 30.

The Toys that Made Him We are joined by the CEO of the Nacelle Toy Company and producer, Brian Volk-Weiss. Brian is a super cool nerd who has helped bring forward some of the media we have loved, such as "The Toys That Made Us", "RoboForce", so many comedy specials, and of course, the Gates McFadden podcast called "InvestiGates". Brian discusses his childhood, the toys that made him, and how he became the nerd he is today. Come join the ride as we learn about all things Brain and share some laughs with one of the coolest guys you will ever get a chance to meet. For more information on Brian Volk-Weiss, please visit the following - Instagram - @brianvolkweiss and @nacellecompany Check out - RoboForce: The Animated Series, on Tubi Please donate to PANCAN.ORG to help us fight against Pancreatic Cancer. Donate here at this link OR scan the QR Code in the top right of the screen - http://support.pancan.org/goto/fsfpopcast For more on our show partners - Bones Coffee - http://www.bonescoffee.com/FSFPOPCAST and use code FSFPOPCAST Idea Farm - www.ideafarm.store - use discount code FSF15 Level Up Sabers https://bit.ly/FSFLevelUpSabers Win free loot - sign up here - www.fsfpopcast.com/contact For more on our Show - Join our Patreon: https://patreon.com/fsfpopcast Join our Discord! https://discord.gg/cpry4fCDTq Visit our website: https://www.fsfpopcast.com FSF PopCast on BlueSky, Instagram, Threads, and Facebook - @fsfpopcast This podcast is powered by Pinecast.

The Toys that Made Him We are joined by the CEO of the Nacelle Toy Company and producer, Brian Volk-Weiss. Brian is a super cool nerd who has helped bring forward some of the media we have loved, such as "The Toys That Made Us", "RoboForce", so many comedy specials, and of course, the Gates McFadden podcast called "InvestiGates". Brian discusses his childhood, the toys that made him, and how he became the nerd he is today. Come join the ride as we learn about all things Brain and share some laughs with one of the coolest guys you will ever get a chance to meet. For more information on Brian Volk-Weiss, please visit the following - Instagram - @brianvolkweiss and @nacellecompany Check out - RoboForce: The Animated Series, on Tubi Please donate to PANCAN.ORG to help us fight against Pancreatic Cancer. Donate here at this link OR scan the QR Code in the top right of the screen - http://support.pancan.org/goto/fsfpopcast For more on our show partners - Bones Coffee - http://www.bonescoffee.com/FSFPOPCAST and use code FSFPOPCAST Idea Farm - www.ideafarm.store - use discount code FSF15 Level Up Sabers https://bit.ly/FSFLevelUpSabers Win free loot - sign up here - www.fsfpopcast.com/contact For more on our Show - Join our Patreon: https://patreon.com/fsfpopcast Join our Discord! https://discord.gg/cpry4fCDTq Visit our website: https://www.fsfpopcast.com FSF PopCast on BlueSky, Instagram, Threads, and Facebook - @fsfpopcast This podcast is powered by Pinecast.

Today's guest is Andy Campbell, a resilient survivor and inspirational author who has overcome numerous life-altering challenges, including a battle with Stage 4 Pancreatic Cancer. He talked about his 15 core beliefs that empowered him (and can empower us) to navigate through life's labyrinth in his book "Overcoming Life's Toughest Setbacks: 15 Breakthrough Core Beliefs to Transform Challenges into Opportunities!"We talk about Pancreatic Cancer, genetic testing and targeted therapies, the power of resilience, insatiable curiosity, and so much more! Andy is an amazing example of overcoming huge setbacks and inspiring others to do the same.Resources:Andy's website: https://www.askandycampbell.com/Andy's LinkedIn: https://www.linkedin.com/company/ask-andy-campbell/Andy's Book on Amazon: Overcoming Life's Toughest Setbacks: 15 Breakthrough Core Beliefs to Transform Challenges into Opportunities!Follow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

In this JCO Article Insights episode, host Jospeh Mathew summaries Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial, by Palmer, et al published December 5, 2024. Transcript Joseph Matthew: Hello and welcome to the Journal of Clinical Oncology Article Insights. I'm your host, Joseph Matthew, and today we will be discussing the article "Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma with Adjuvant Gemcitabine plus Capecitabine Compared to Modified FOLFIRINOX from the ESPAC-4 and the PRODIGE 24 Trials" by Dr. Palmer et al. To summarize the relevant evidence, the ESPAC-4 was a European phase 3 multicenter randomized clinical trial published in 2017 comparing adjuvant gemcitabine and capecitabine (GemCap) with gemcitabine monotherapy following macroscopic margin-negative resections for operable pancreatic ductal adenocarcinoma (PDAC). The trial had included non-metastatic patients aged 18 years or older, World Health Organization (WHO) performance scores of 2 or less, creatinine clearance of at least 50 mL/min, and a life expectancy of over three months who had not received any prior anticancer treatment. Patients who had undergone R2 resections were selectively excluded. Eligible participants were randomized 1:1 within 12 weeks of pancreatectomy to one of the two treatment arms, with chemotherapy initiated within two weeks from the date of randomization. The regimens involved six cycles, each lasting four weeks, for an overall duration of 24 weeks. In the monotherapy arm, gemcitabine dosed at 1 g/m² was given as an intravenous infusion once a week for three weeks, followed by one week off. In the GemCap arm, capecitabine dosed at 1660 mg/m² was added to gemcitabine, given daily for three weeks, followed by one week off. Patients were followed up every three months, with the primary endpoint being overall survival (OS). The study showed that at a median follow-up of 43.2 months, GemCap was associated with a significantly longer OS than gemcitabine alone. Subsequently, in 2018, the Phase 3 randomized PRODIGE 24 trial was conducted in centers across France and Canada, comparing adjuvant modified FOLFIRINOX (mFOLFIRINOX) with gemcitabine in a similar subset of patients with resected PDAC and reported longer OS with the mFOLFIRINOX regimen. This study, however, had more restrictive eligibility criteria when compared to ESPAC-4, including patients aged under 80 years, WHO performance status of 0 or 1, with no significant cardiovascular disease, and a postoperative serum CA 19-9 of less than 180 U/mL. There was hence a subset of ESPAC-4 patients who did not meet the eligibility criteria for mFOLFIRINOX as set by the PRODIGE 24. The present study was conducted to estimate the overall 5-year survival rates for patients of ESPAC-4 receiving GemCap and gemcitabine, further stratifying survival in either arm according to the status of the surgical margins (R status) and the resected nodes (N status), and also to investigate whether GemCap retained a survival benefit over gemcitabine in PRODIGE 24-ineligible patients. A total of 732 patients, evenly distributed between both arms, were followed up for a median period of 104 months. Adjuvant GemCap was found to retain its survival advantage over gemcitabine, with a significantly longer median OS of 31.6 months when compared to 28.4 months with gemcitabine alone. Further subgroup analysis was performed with reference to the resection margins and the nodal status. As a reminder, in the ESPAC-4 trial, 60% of patients were found to have microscopically positive margins (an R1 resection), and 80% were node-positive. The difference in survival was greater in patients undergoing microscopic margin-negative resections (R0) who experienced a median OS of 49.9 months with GemCap when compared to 32.2 months with gemcitabine. Node-negative patients also had a significantly greater 5-year OS rate with GemCap of 59% versus 53% with gemcitabine monotherapy. However, it is important to note that no significant difference in survival outcomes was observed in margin-positive (R1) or node-positive patients in the two arms. The investigators also evaluated GemCap in the subgroup of 193 patients (comprising 26.4% of the ESPAC-4 cohort) who were not considered to have met the eligibility criteria for PRODIGE 24. The survival benefit of combination therapy was retained in this group, with patients receiving GemCap experiencing a median survival of 25.9 months compared to 20.7 months with adjuvant gemcitabine. Although cross-trial comparisons have limited validity, good agreement was noted in adverse grade 3 or greater toxicity associated with the control gemcitabine arms of ESPAC-4 and PRODIGE 24, serving as the basis for a qualitative comparison of toxicities between mFOLFIRINOX and GemCap. Neutropenia was more prevalent in the GemCap arm, affecting 40.8% of patients compared to 28.4% with mFOLFIRINOX. However, granulocyte colony-stimulating factor (G-CSF) was administered to 62.2% of patients in PRODIGE 24. Palmar-plantar erythrodysesthesia (PPE) was also more prevalent with GemCap. Patients on mFOLFIRINOX were more likely to observe grade 3 or greater fatigue, diarrhea, nausea and vomiting, sensory peripheral neuropathy, and paresthesias. The investigators concluded that GemCap was the standard adjuvant treatment for patients with PDAC undergoing an upfront resection who were not feasible for mFOLFIRINOX. Further exploratory analysis revealed that patients under the age of 70 who had undergone a microscopic margin-negative (R0) resection for node-negative PDAC were likely to derive an OS benefit from the addition of capecitabine to gemcitabine in the adjuvant setting. In contrast, mFOLFIRINOX would be more effective than gemcitabine in patients with positive margins (R1) or involved nodes, as per the PRODIGE 24 trial. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit ASCO.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

FSF SideBar - Andor Season 2 Review The long awaited arrival of Andor season 2 is finally here. Tonight we review episodes 1-3 THERE WILL BE SPOILERS!! Come join us. Have some fun. Let's talk Star Wars! Please donate to PANCAN.ORG to help us fight against Pancreatic Cancer. Donate here at this link OR scan the QR Code in the top right of the screen - http://support.pancan.org/goto/fsfpopcast For more on our show partners - Bones Coffee - http://www.bonescoffee.com/FSFPOPCAST and use code FSFPOPCAST Idea Farm - www.ideafarm.store - use discount code FSF15 Level Up Sabers https://bit.ly/FSFLevelUpSabers Win free loot - sign up here - www.fsfpopcast.com/contact For more on our Show - Join our Patreon: https://patreon.com/fsfpopcast Join our Discord! https://discord.gg/cpry4fCDTq Visit our website: https://www.fsfpopcast.com FSF PopCast on BlueSky, Instagram, Threads, and Facebook - @fsfpopcast This podcast is powered by Pinecast.

FSF SideBar - Andor Season 2 Review The long awaited arrival of Andor season 2 is finally here. Tonight we review episodes 1-3 THERE WILL BE SPOILERS!! Come join us. Have some fun. Let's talk Star Wars! Please donate to PANCAN.ORG to help us fight against Pancreatic Cancer. Donate here at this link OR scan the QR Code in the top right of the screen - http://support.pancan.org/goto/fsfpopcast For more on our show partners - Bones Coffee - http://www.bonescoffee.com/FSFPOPCAST and use code FSFPOPCAST Idea Farm - www.ideafarm.store - use discount code FSF15 Level Up Sabers https://bit.ly/FSFLevelUpSabers Win free loot - sign up here - www.fsfpopcast.com/contact For more on our Show - Join our Patreon: https://patreon.com/fsfpopcast Join our Discord! https://discord.gg/cpry4fCDTq Visit our website: https://www.fsfpopcast.com FSF PopCast on BlueSky, Instagram, Threads, and Facebook - @fsfpopcast This podcast is powered by Pinecast.

Cohort study evaluated the use of ablative radiation therapy (A-RT) as a noninvasive alternative to surgery in 25 patients with technically resectable pancreatic ductal adenocarcinoma (PDAC) who were ineligible for surgery due to comorbidities. Conducted at Memorial Sloan Kettering Cancer Center between 2016 and 2022, the study found that A-RT, delivered with high precision and dose intensity, provided promising local control and overall survival, with a 2-year OS rate of 43.7% and manageable toxicity. Despite advanced age, poor performance status, and limited chemotherapy use in the cohort, outcomes suggest A-RT may be a viable local therapy for select patients with resectable PDAC, warranting further prospective investigation.Link to Arcticlehttps://jamanetwork.com/journals/jamaoncology/article-abstract/2832566

See omnystudio.com/listener for privacy information.

Why are grocery prices so high? Is it because of tariffs? Is it because of supply chain costs, or the Bird Flu? And how can you continue to budget while the cost of most products continue to increase? On today's episode of The Crushing Debt Podcast, Shawn & George discuss these issues, including some strategies to deal with the rising cost of goods, including Budgeting Using Cash Envelopes (or a similar system) Buying off-brand products Using coupons or loyalty discounts Buying in bulk Eating everything you buy (no waste) Creating a meal plan Using a meal delivery service Making a list and sticking to it and More! Let us know what budget-conscious tools you use. If you enjoy this episode, please share it with your friends! Please also visit our sponsor, Sam Cohen of Attorneys First Insurance for Attorneys and Title Companies looking to get a quote on Errors & Ommissions (malpractice) Insurance coverage. www.AttorneysFirst.com.   Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com.  And please consider a donation to Pancreatic Cancer research and education by joining Shawn's team at MY Legacy Striders: http://support.pancan.org/goto/MYLegacy8  The Purple Stride Walk is THIS SATURDAY, April 26, 2025.  

When life throws unimaginable challenges—raising four kids, one with special needs, and then losing your husband to cancer—what comes next?For author and advocate Julie Barth, the answer was purpose.In this moving episode, Julie shares her journey from family chaos to crisis and ultimately to the creation of CJB Outreach, a nonprofit named for her late husband, Colin James Barth. The organization supports women-led households in crisis, offering assistance before families lose everything. Julie also discusses her books (Notes from a Blackberry and the upcoming From Blackberries to Thorns), and how her daughter Tatum, born with primordial dwarfism, found her voice through art—with proceeds now benefiting the nonprofit.A beautiful conversation about love, legacy, motherhood, and resilience.

The Low End Theory Sofia Yepes, actress, producer, and host of the Sana Sana Single Mama podcast, joins our show to talk about her new movie, "The Low End Theory". We also discuss the importance of life experience in her work, the importance of community, both as a Latina and as a single mother. Sofia shared lots of great information here. You can find her movie, "The Low End Theory," exclusively on the In The Black TV Network. Watchable on your computer, mobile device, Roku and other streaming devices. For more about Sofia Yepes, please visit the following - All Socials - @Sofiajyepes In the Black Network - Instagram Handle - @InTheBlackNetwork Please donate to PANCAN.ORG to help us fight against Pancreatic Cancer. Donate here at this link OR scan the QR Code in the top right of the screen - http://support.pancan.org/goto/fsfpopcast For more on our show partners - Bones Coffee - http://www.bonescoffee.com/FSFPOPCAST and use code FSFPOPCAST Idea Farm - www.ideafarm.store - use discount code FSF15 Level Up Sabers https://bit.ly/FSFLevelUpSabers Win free loot - sign up here - www.fsfpopcast.com/contact For more on our Show - Join our Patreon: https://patreon.com/fsfpopcast Join our Discord! https://discord.gg/cpry4fCDTq Visit our website: https://www.fsfpopcast.com FSF PopCast on BlueSky, Instagram, Threads, and Facebook - @fsfpopcast This podcast is powered by Pinecast.

In this powerful episode of The Clinical Research Coach, we sit down with Kay Kays — a 30-year pancreatic cancer survivor and passionate patient advocate. Kay's story is nothing short of extraordinary. Diagnosed with one of the most challenging cancers to treat, she not only defied the odds but has spent the last three decades using her voice to push for better patient access to clinical trials.With her signature honesty and infectious energy, Kay shares why she believes clinical trials should be the appetizer — not the dessert — in the treatment journey. We talk survivorship, advocacy, and the urgent need to change how patients are introduced to research as a care option. Whether you're in clinical research, oncology, or simply need a dose of inspiration, this conversation is not to be missed.To learn more about Kay Kays:https://www.linkedin.com/in/kay-kays-2a993649/

The Low End Theory Sofia Yepes, actress, producer, and host of the Sana Sana Single Mama podcast, joins our show to talk about her new movie, "The Low End Theory". We also discuss the importance of life experience in her work, the importance of community, both as a Latina and as a single mother. Sofia shared lots of great information here. You can find her movie, "The Low End Theory," exclusively on the In The Black TV Network. Watchable on your computer, mobile device, Roku and other streaming devices. For more about Sofia Yepes, please visit the following - All Socials - @Sofiajyepes In the Black Network - Instagram Handle - @InTheBlackNetwork Please donate to PANCAN.ORG to help us fight against Pancreatic Cancer. Donate here at this link OR scan the QR Code in the top right of the screen - http://support.pancan.org/goto/fsfpopcast For more on our show partners - Bones Coffee - http://www.bonescoffee.com/FSFPOPCAST and use code FSFPOPCAST Idea Farm - www.ideafarm.store - use discount code FSF15 Level Up Sabers https://bit.ly/FSFLevelUpSabers Win free loot - sign up here - www.fsfpopcast.com/contact For more on our Show - Join our Patreon: https://patreon.com/fsfpopcast Join our Discord! https://discord.gg/cpry4fCDTq Visit our website: https://www.fsfpopcast.com FSF PopCast on BlueSky, Instagram, Threads, and Facebook - @fsfpopcast This podcast is powered by Pinecast.

FSF PopCast Happy Hour - LIVE! Welcome back to another FSF PopCast Happy Hour! We have SO much to talk about Star Wars Celebration announcements Fantastic Four Trailer Andor Season 2 The Last of Us Pedro Pascal And honestly, other topics will sneak in .. they ALWAYS do! Please donate to PANCAN.ORG to help us fight against Pancreatic Cancer. Donate here at this link OR scan the QR Code in the top right of the screen - http://support.pancan.org/goto/fsfpopcast For more on our show partners - Bones Coffee - http://www.bonescoffee.com/FSFPOPCAST and use code FSFPOPCAST Idea Farm - www.ideafarm.store - use discount code FSF15 Level Up Sabers https://bit.ly/FSFLevelUpSabers Win free loot - sign up here - www.fsfpopcast.com/contact For more on our Show - Join our Patreon: https://patreon.com/fsfpopcast Join our Discord! https://discord.gg/cpry4fCDTq Visit our website: https://www.fsfpopcast.com FSF PopCast on BlueSky, Instagram, Threads, and Facebook - @fsfpopcast This podcast is powered by Pinecast.

Today's guests are Anna Berkenblit, Chief Scientific and Medical Officer at the Pancreatic Cancer Action Network, and Sudheer Doss, Chief Business Officer at PanCAN. The Pancreatic Cancer Action Network is the leading organization dedicated to advancing progress against pancreatic cancer. It empowers patients and caregivers, drives early detection strategies, and revolutionizes the development of advanced and personalized treatments.TPM E45 highlights >⁠⁠⁠⁠⁠⁠⁠⁠Episode 45 links:Anna Berkenblit on LinkedInSudheer Doss on LinkedInPanCANFor access to data through PanCAN's SPARK platform, please visit: PanCAN.org/sparkFor more information, contact PanCAN Patient Services with questions about any type of pancreatic cancer – we are here to help.

FSF PopCast Happy Hour - LIVE! Welcome back to another FSF PopCast Happy Hour! We have SO much to talk about Star Wars Celebration announcements Fantastic Four Trailer Andor Season 2 The Last of Us Pedro Pascal And honestly, other topics will sneak in .. they ALWAYS do! Please donate to PANCAN.ORG to help us fight against Pancreatic Cancer. Donate here at this link OR scan the QR Code in the top right of the screen - http://support.pancan.org/goto/fsfpopcast For more on our show partners - Bones Coffee - http://www.bonescoffee.com/FSFPOPCAST and use code FSFPOPCAST Idea Farm - www.ideafarm.store - use discount code FSF15 Level Up Sabers https://bit.ly/FSFLevelUpSabers Win free loot - sign up here - www.fsfpopcast.com/contact For more on our Show - Join our Patreon: https://patreon.com/fsfpopcast Join our Discord! https://discord.gg/cpry4fCDTq Visit our website: https://www.fsfpopcast.com FSF PopCast on BlueSky, Instagram, Threads, and Facebook - @fsfpopcast This podcast is powered by Pinecast.

Spring is when many people spring clean their home. But how many of us Spring Clean our finances? How many of us declutter our debt? April is also Financial Literacy Month, and for most of the Country April is the month when income tax returns are due.  Did you file on time, or did you file for an extension? On this week's episode, Shawn & George talk about how to spring clean your debt, which is very similar to spring cleaning your home: (1) declutter - what expenses can you reduce or eliminate, (2) pick your cleaning tools - how do you want to eliminate debt, through consolidation, avalanche, snowball, or something else, and (3) stay organized - it's easier to remain debt free if you remain organized. Let us know if you enjoy this episode and, if so, please share it with your friends! Please also visit our sponsor Sam Cohen of Attorneys First Insurance for Attorneys and Title Companies looking to get a quote on Errors & Ommissions (malpractice) Insurance coverage. www.AttorneysFirst.com.   Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com. And please consider a donation to Pancreatic Cancer research and education by joining Shawn's team at MY Legacy Striders: http://support.pancan.org/goto/MYLegacy8  

Pancreatic cancer is one of the deadliest types of cancer. It's known as the “silent killer” because, by the time you know you have it, it's often too late. Pay attention to these 7 early warning signs of pancreatic cancer.1. Sudden unexpected weight lossA problem with the pancreas can affect digestion and appetite, which can cause you to lose weight unexpectedly. 2. Abdominal painThis is typically dull, persistent pain that can radiate to the left shoulder. Sometimes, it shows up as radiating pain in the belly button that extends into the spine and often feels worse after eating. 3. Jaundice This is characterized by yellowing of the whites of the eyes and rust-colored urine caused by bile backing up into the blood. TUDCA can be a good remedy for this! Take two on an empty stomach twice a day to open the bile ducts. 4. Chronic diarrhea Most pancreatic cancer affects the part of the pancreas that is responsible for digestive enzymes, which can often lead to chronic diarrhea. 5. Diabetes A tumor in the pancreas can disrupt the cells that produce insulin, contributing to diabetes. 6. Feeling full quickly Pancreatic cancer can cause you to feel full and bloated even If you've hardly had anything to eat.7. Persistent fatigue This can be described as overwhelming, chronic fatigue that doesn't improve with more sleep.Don't consume sugar if you have pancreatic cancer!Risk factors for pancreatic cancer include the following:•Smoking tobacco •Type 2 diabetes •Obesity •Alcohol consumption•Genetic factors•Vitamin D deficiency Vitamin D may help shrink cancer and enhance the immune system's ability to fight cancer.To help prevent pancreatic cancer:•Ensure you're getting enough sleep •Reduce stress•Exercise •Practice intermittent fasting Incorporating anti-cancer foods such as cruciferous vegetables, green tea, garlic, and berberine may help. Dr. Eric Berg DC Bio:Dr. Berg, age 59, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the author of the best-selling book The Healthy Keto Plan, and is the Director of Dr. Berg Nutritionals. He no longer practices, but focuses on health education through social media.

How does your financial life change when you are childfree? What is the difference between FIRE and FILE? How does your investing change when you are childfree? How does childfree impact your estate planning and long-term financial goals change? How often have you asked a newlywed couple, "so when are you having kids?" How often have you asked a couple married long-term, "any plans for kids soon?"  There is a growing number of married couples who are childfree, sometimes for medical reasons, and sometimes by voluntary choice. How can people with kids be supportive of their friends who have chosen (voluntarily or involuntarily) to live a childfree life. On this week's episode of the Crushing Debt Podcast, Shawn and George interview Jay Zigmont, PhD, MFA, CFP. Dr. Jay and his wife are childfree, and it has profoundly shaped how they approach their finances. When Dr. Jay searched for financial advice, he realized that most of it assumes you have kids, which didn't align with their goals. That's why he founded Childfree Wealth®—to offer financial planning tailored specifically to the unique needs of the childfree community. You can reach Dr. Jay at his website, www.childfreewealth.com, and check out his book, The Childfree Guide to Life & Money, available on the website and wherever your favorite books are sold. Let us know if you enjoy this episode and, if so, please share it with your friends! Please also visit our sponsor, Sam Cohen of Attorneys First Insurance for Attorneys and Title Companies looking to get a quote on Errors & Ommissions (malpractice) Insurance coverage. www.AttorneysFirst.com.   Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com.   And please consider a donation to Pancreatic Cancer research and education. The Purple Stride walk is just a few weeks away, on April 26, 2025! You can join Shawn's team at MY Legacy Striders: http://support.pancan.org/goto/MYLegacy8. 

In this heartfelt episode of the Project Purple Podcast, host Dino Verrelli sits down with Mark Wade, a stage III pancreatic cancer survivor, to share his deeply personal journey from diagnosis to remission. Mark opens up about the shock of his diagnosis in April 2021, the whirlwind of chemotherapy and radiation, and undergoing a Whipple procedure later that year. Mark reflects on the emotional toll of treatment and the unexpected challenges that came after, including anxiety and the difficulty of adjusting to life post-treatment. He shares how therapy helped him process his experience and why he believes in the importance of speaking honestly about mental health during and after cancer. Throughout the conversation, Mark also discusses the impact of his diagnosis on his career in education and the powerful support he received from colleagues, friends, and his wife. His story is one of vulnerability, resilience, and the ongoing work of healing—physically, mentally, and emotionally. Subscribe to the Project Purple Podcast for more powerful stories from the pancreatic cancer community. If you'd like to donate to Project Purple's mission of a world without pancreatic cancer, please visit https://www.projectpurple.org/. To learn more about Project Purple, visit https://www.projectpurple.org/ or follow us on social media at these links: https://www.facebook.com/Run4ProjectPurple https://www.instagram.com/projectpurple/ https://twitter.com/Run4Purple https://www.youtube.com/channel/UCgA8nVhUY6_MLj5z3rnDQZQ

This week on the Believe Big Podcast, we welcome Chris Joseph, an eight-and-a-half-year survivor of stage 3 pancreatic cancer who defied the odds—and the statistics—by completely transforming his approach to healing.At one point, Chris was told that chemotherapy was his only real option. But when the treatment left him even sicker and failed to stop the cancer, he made a courageous decision: to take control of his health and walk a different path—one guided by faith, intentional living, and a commitment to his own well-being.In this inspiring episode, Chris shares:The pivotal moment he knew he had to walk away from conventional treatmentWhy stepping into the role of CEO of your own health is essentialThe lifestyle and emotional changes that played a key role in his recoveryA revealing look at cancer statistics—and why you shouldn't let them define your outcomeHow he's now guiding others as a coach and advocate to reclaim their power and pursue healingChris's story is a testament to what can happen when you combine faith, courage, and a willingness to explore every avenue toward healing. You don't want to miss this one.Learn more about Chris here:  Terrain NavigatorsSuggested Resources:Chris's website: terrainnavigators.comBook: Life Is A Ride: My Unconventional Journey of Cancer RecoveryUpcoming Book: The Kitchen Sink Approach to CancerRadical Remission Project: radicalremission.comThe Metabolic Approach to Cancer by Dr. Nasha WintersSend us Fan Mail! Click here >Your donations power our podcast's mission to support cancer patients with hope, insights, and resources. Every contribution fuels our ability to uplift and empower. Join us in making a lasting impact. Donate now!

Join us in this insightful episode of the Oncology Brothers podcast as we dive deep into the current treatment landscape of pancreatic cancer. Drs. Rohit and Rahul Gosain are joined by Dr. Emil Lou, a medical and neuro-oncologist from the University of Minnesota, to discuss the challenges and advancements in managing this complex disease. In this episode, we covered: •⁠  ⁠The importance of a multidisciplinary approach in treating early-stage pancreatic cancer. •⁠  ⁠The role of neoadjuvant and adjuvant therapies, including the latest insights on chemotherapy regimens like FOLFIRINOX, nal-IRI and gemcitabine. •⁠  ⁠The significance of germline and next-generation sequencing (NGS) testing in personalizing treatment plans. •⁠  ⁠The current state of clinical trials and emerging therapies, including PARP inhibitors for BRCA mutations and the implications of ctDNA testing. •⁠  ⁠Prognostic discussions around metastatic pancreatic cancer and the importance of managing side effects to improve patient quality of life. Key takeaways include the necessity of balancing treatment efficacy with adverse events, the critical role of genetic testing, and the need for vigilance regarding venous thromboembolism (VTE) in pancreatic cancer patients. Don't miss this comprehensive discussion that aims to shed light on the ongoing efforts to improve outcomes for patients battling pancreatic cancer.   YouTube: https://youtu.be/HCKQxmOqRTI   Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Subscribe to our channel for more discussions on oncology and stay updated on the latest in cancer treatment!

Episode Summary:In this episode of the Beautifully Broken Podcast, Kyle Samuels—Founder & CEO of Creative Talent Endeavors (CTE)—opens up about his unexpected journey through a pancreatic cancer diagnosis and what it taught him about self-advocacy, resilience, and the importance of early detection. Kyle's story is a raw and inspiring look at how one moment can shift everything—and how listening to your body (and your loved ones) can literally save your life.Together, we explore his role as a disruptor in executive recruiting, the cultural disparities in healthcare, and the power of community when navigating illness. This is a conversation about hope, awareness, and the healing that happens when you embrace being beautifully broken.HIGHLIGHTS[2:52] Kyle breaks down what's broken in traditional recruitment and what he's doing differently [6:05] The Friday night that changed everything: Kyle's mysterious symptoms lead to a shocking discovery [12:05] Why early detection and a simple blood test (CA 19-9) may have saved Kyle's life [17:48] Navigating treatment and the mental/emotional recovery that follows [28:39] Proactive scanning: the game-changer in catching cancer early [30:28] Building the mental strength to handle unexpected health journeys [33:20] Talking about health inequities and why cultural shifts are needed [40:25] Health behavior and awareness in different communities [41:16] Gratitude, healing, and the new mission that emerged from the painCONNECT WITH KYLEWebsite: https://www.hirecte.com/LinkedIn: https://www.linkedin.com/in/kylesamuels/UPGRADE YOUR WELLNESSSilver Biotics Wound Healing Gel: https://bit.ly/3JnxyDD (30% off)(Use Code: BEAUTIFULLYBROKEN for Discount)Saga Bands: https://ca.saga.fitness/?ref=titvyccmCode: beautifullybrokenStemRegen: https://www.stemregen.co/products/stemregen?_ef_transaction_id=&oid=1&affid=52Code: beautifullybrokenLightPathLED https://lightpathled.pxf.io/c/3438432/2059835/25794Code: beautifullybroken CONNECT WITH FREDDIE Check out my website and store: (http://www.beautifullybroken.world) Instagram: (https://www.instagram.com/beautifullybroken.world/) YouTube: (https://www.youtube.com/@BeautifullyBrokenWorld)

In this fascinating episode of the Project Purple Podcast, CEO & Founder Dino Verrelli welcomes Dr. Cosimo Commisso, interim director and deputy director of the NCI-designated Cancer Center at Sanford Burnham Prebys Medical Discovery Institute. A leader in cancer metabolism research, Dr. Commisso shares groundbreaking insights into how pancreatic cancer cells survive and thrive—and what that means for future treatments. Dr. Commisso breaks down the complex science behind tumor microenvironments, metabolic vulnerabilities, and the latest advances in targeting pancreatic cancer at a cellular level. He also discusses the challenges researchers face, the hope emerging from new studies, and why funding for this research is more critical than ever. Whether you're a patient, caregiver, advocate, or science enthusiast, this episode delivers a powerful look at the cutting edge of pancreatic cancer research and the fight for better treatments. Subscribe to the Project Purple Podcast for more inspiring stories. If you'd like to donate to Project Purple's mission of a world without pancreatic cancer, please visit https://www.projectpurple.org/. To learn more about Project Purple, visit https://www.projectpurple.org/ or follow us on social media at these links: https://www.facebook.com/Run4ProjectPurple https://www.instagram.com/projectpurple/ https://twitter.com/Run4Purple https://www.youtube.com/channel/UCgA8nVhUY6_MLj5z3rnDQZQ

They took care of us, but what do we do when it's time to take care of them? Can you help care for your aging parents or grandparents, while also taking care of your kids? Do you find yourself a part of the "sandwich generation?" In this week's episode of the Crushing Debt Podcast, Shawn & George discuss the hidden costs and other pitfalls of helping the older generation, while still potentially taking care of a younger generation, and all while maintaining your sanity! We discuss topics like: Rising Medical Bills; Preventing Fraud and other Scams; Assisting with Financing and Budgeting; Whether you should be on your parents' bank accounts; Whether you should be on the title to your parents' home; How to responsibly spend savings or retirement; and What to do when siblings are involved. Let us know if you enjoy this episode and, if so, please share it with your friends! Please also visit our sponsor Sam Cohen of Attorneys First Insurance for Attorneys and Title Companies looking to get a quote on Errors & Ommissions (malpractice) Insurance coverage. www.AttorneysFirst.com.   Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com. And please consider a donation to Pancreatic Cancer research and education by joining Shawn's team at MY Legacy Striders: http://support.pancan.org/goto/MYLegacy8  

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain continue their ToxCheck series, focusing on the management of side effects associated with treatments for pancreatic cancer. Join us as we dive deep into the use of key drugs such as 5-FU, oxaliplatin, irinotecan, liposomal irinotecan, and the combination of gemcitabine and nab-paclitaxel. We are joined by esteemed guests Dr. Rachna Shroff from the University of Arizona and Dr. Midhun Malla from the University of Alabama, who share their insights and clinical pearls on managing the challenging side effects of these therapies. Key topics discussed include: •⁠  ⁠The utility of 5-FU bolus and leucovorin in treatment regimens •⁠  ⁠Managing common side effects like diarrhea, mucositis, and neuropathy •⁠  ⁠The importance of preemptive strategies in side effect management •⁠  ⁠Insights on liposomal irinotecan and its tolerability •⁠  ⁠The impact of gemcitabine and nab-paclitaxel on quality of life Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable information on optimizing treatment while maintaining patient quality of life. YouTube: https://youtu.be/KByOGRpzFMQ Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to check out our other ToxCheck episodes on antibody drug conjugates, CAR-T, and anti-EGFR drugs used in colorectal cancer. Subscribe for more insights from the Oncology Brothers!  

Exploring the stress-cancer link—real, or unduly stigmatizing for people with cancer? Is coffee the most chemically-treated food? Is there a link between fluoride and pineal gland dysfunction? TV ads for oral supplement for dry eyes tout a dubious formula (and what could work better); Could meat make America healthy again?

Pancreatic cancer is notoriously difficult to treat, and about 90% of diagnosed patients die from the disease. A team at Memorial Sloan Kettering has been working to improve those outcomes by developing a new mRNA vaccine for pancreatic cancer.A few years ago, the team embarked on a small trial to test the vaccine's safety. Sixteen patients with pancreatic cancer received it, and even though it was a small study, the results were promising: Half the participants had an immune response, and in those patients the cancer hadn't relapsed after 18 months.This week, the team released a new study in Nature following those same patients, and found six out of eight who responded to the vaccine in the first study did not have their cancer return more than three years later.Joining host Flora Lichtman to talk about these results, and what they could mean for the future of cancer treatment, is study author and surgeon Dr. Vinod Balachandran, director of The Olayan Center for Cancer Vaccines at Memorial Sloan Kettering, based in New York City.Transcripts for each segment will be available after the show airs on sciencefriday.com.  Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.